Retrospective cohort study evaluates treatment outcomes of oral cephalosporins in bacteremia from urinary infections, suggesting no significant differences based on cefazolin levels.
Cefazolin breakpoints differ for the treatment of Enterobacterales urinary tract infections and systemic infections. A retrospective, exploratory cohort study of 148 patients found no difference in 30-day treatment outcomes based on the blood culture cefazolin minimum inhibitory concentration (≤2 mcg/mL versus 4–16 mcg/mL) for patients transitioned to PO cephalosporins for the treatment of Escherichia coli , Klebsiella pneumoniae , or Proteus mirabilis bacteremia secondary to a urinary source. Further research should confirm these findings.
No takes yet. Share an insight, caveat, or question.
Kobasuk et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: